제빵기는 가라 @dmswn522

🫁 Unresectable Stage III NSCLC: Current State of the Art. The management of unresectable stage III NSCLC continues to evolve. cCRT remains the backbone of treatment, while consolidation durvalumab (PACIFIC) and osimertinib for EGFR-mutated disease (LAURA) have redefined the standard of care. Precision radiotherapy and biomarker-driven strategies are shaping the next era of treatment. 📖 Am Soc Clin Oncol Educ Book DOI 👉🏻 doi.org/10.1200/EDBK-2… #CánCare #NSCLC #lcsm #thoraciconcology #immunotherapy #precisiononcology

keyboard_arrow_left Previous keyboard_arrow_right Next

🫁 Immunotherapy Rechallenge in NSCLC. The largest meta-analysis to date (10 RCTs, n=3,081) showed that PD-(L)1 rechallenge provided modest OS (HR 0.91) and PFS (HR 0.89) benefits, with no ORR improvement. No benefit was observed in primary resistance, while patients with acquired resistance appeared more likely to benefit (OS HR 0.86). Resistance phenotype matters. 📖 Cancer Treatment Reviews. DOI 👉🏻 doi.org/10.1016/j.ctrv… #CánCare #NSCLC #lcsm #ThoracicOncology #Immunotherapy #ICI

keyboard_arrow_left Previous keyboard_arrow_right Next

🦴Bone health in cancer ESMO guideline summary #cancer #oncology #MedX #bone

#CIOT26 Dr. @RamalingamMD compares the approved HER2 targeted agents for NSCLC. Trastuzumab deruxtecan first approved agent but oral options like sevabertinib very appealing and zongertinib now with approval as first line therapy. And for NRG1, zenocutuzumab preferred.

keyboard_arrow_left Previous keyboard_arrow_right Next

🫁 Another phase III trial is making the case for upfront treatment intensification in EGFR-mutated NSCLC. AENEAS2 evaluated first-line aumolertinib ± platinum-pemetrexed in advanced EGFR-mutated NSCLC. Study population: EGFR Ex19del or L858R mutations Treatment-naïve advanced NSCLC ECOG 0-1 Stable brain metastases allowed 🔹 Aumolertinib vs 🔸 Aumolertinib + platinum-pemetrexed → maintenance aumolertinib + pemetrexed Results: ⏳ Median PFS 28.9 months vs 18.9 months 📉 53% lower risk of progression or death HR 0.47 (95% CI 0.37-0.60) 🧠 Benefit seen in patients with brain metastases 🧬 Benefit seen in L858R-mutant disease The trade-off? ⚠️ Grade 3-4 neutropenia 55% vs 1% ⚠️ Grade 3-4 thrombocytopenia 20% vs 1% Clinical takeaway: After FLAURA2, MARIPOSA, and now AENEAS2, the question is no longer whether intensification improves PFS. The question is which patients should receive it upfront. 📖 Full paper in comment ⬇️ @asco @myesmo @oncoalert #OncoTwitter #MedTwitter #NSCLC #LungCancer

Analysis using Korean insurance claims data: of 10,275 pts receiving immunotherapy for NSCLC, 7.6% complete planned 2y - no significant difference with various agents. Note that after 3y off therapy, 42% of pts received subsequent treatment. lungcancerjournal.info/article/S0169-…

Early morning learning from Dr. @ZPiotrowskaMD discussing new standards of care for HER2 mutant NSCLC. HER2 ADCs like T-DXd giving way in the first line setting to TKIs like zongertinib - but will the future for advanced HER2+ NSCLC be combinations?

keyboard_arrow_left Previous keyboard_arrow_right Next

🚨 Our phase 1b/2a study of fostrox + lenvatinib in pretreated advanced HCC is now published in @CCR_AACR @AACR 👉 Fostrox plus lenvatinib demonstrated promising efficacy as a 2L or 3L treatment for advanced HCC after prior ICI. 👉 ORR was 24%, DCR 81%, median TTP 10.9 months, median PFS 6.7 months, and median OS 13.7 months. 👉 Liver-targeted fostrox induced tumor-selective DNA damage without causing treatment-related liver function deterioration. @ILCAnews @EASLnews @ASCO @myESMO Full text: doi.org/10.1158/1078-0… #HCC #LiverCancer #Immunotherapy #Fostrox #Lenvatinib #Secondlinetreatment

What are plenary sessions for ASCO 2026 ? Titles are just out Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri

What did ASCO 2026 change? Some standards of care have now moved by years. That almost never happens. BRAF colorectal, pancreatic KRAS, and DDLPS sarcoma are three of oncology's hardest diseases SOC moved by > 1yr: ▫️BRAF mCRC: 15.1 → 30.3 months OS ▪️Pancreatic KRAS: 6.7 → 13.2 months OS 🏆 ▪️DDLPS sarcoma: 1.5 → 9.7 months PFS ⭐️ (sarcoma went from "nothing" to a win). Myeloma, GIST, HR+/HER2- breast, uveal melanoma, bladder, prostate, and RET+ lung cancer moved too. This is what decades of funded science look like when it compounds. - - - - - Source: Jori (@jori_health) 𝘗𝘭𝘰𝘵 𝘱𝘦𝘦𝘳-𝘳𝘦𝘷𝘪𝘦𝘸𝘦𝘥 𝘣𝘺 𝘦𝘪𝘨𝘩𝘵 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘦𝘹𝘱𝘦𝘳𝘵𝘴. 𝘛𝘩𝘢𝘯𝘬 𝘺𝘰𝘶 <3 - - - - -

🚨 Stage III unresectable NSCLC has quietly become one of the biggest precision oncology success stories. A decade ago: ➡️ Median OS ~2 years Today: ✅ PACIFIC: mOS 47.5 months ✅ LAURA: mPFS 39.1 months in EGFR-mutant disease ✅ 5-year OS approaching 43% The key lesson? Every patient needs upfront molecular testing. 🧬 EGFR-mutant → Osimertinib 🛡️ EGFR wild-type → Durvalumab The era of “all stage III patients get the same treatment” is over. Full paper in comment below ⬇️ #OncoTwitter #MedTwitter #LungCancer @OncoAlert @myesmo @esmo_open @JCO_ASCO

Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy. TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes: • Median OS 10.0 vs 11.8 months • No improvement in response rate • More adverse events and treatment-related deaths While disappointing, these results should not be extrapolated to all consolidative TRT strategies. One key difference from SAKK 15/19 is timing: RT here was delivered concurrently with ongoing chemoimmunotherapy, whereas SAKK 15/19 administers TRT after completion of induction treatment and no major toxicity was detected Perhaps the lesson is not that thoracic RT has no role, but that timing matters. pubmed.ncbi.nlm.nih.gov/41344066/ #ASCO26 #SCLC #LungCancer #Radiotherapy

keyboard_arrow_left Previous keyboard_arrow_right Next

Human scientific ingenuity and hardwork, not AI. Human clinical trialists and patients, not AI The standing ovation at #ASCO26 for the unprecedented results in metastatic pancreatic cancer with daraxonrasib an oral RAS inhibitor is the result of research excellence and perseverance, and a witness to this. AI won’t do the work or run the trials to make these advances. It can make the process easier in the future. But you still need human ingenuity and hard works to take a chemical and make it an effective approved medicine. Institutions and companies must nurture the human talent. Academic medicine is bleeding talent. Leaders are appointed for pliability over excellence. With NIH funding of new investigators at an all time low, coupled with institutions and organizations extolling the efficiencies and prioritizing the virtues of AI, we are at risk slowing down our ability in drug development. nejm.org/doi/full/10.10…

@ASCO #ASCO26 Highlight of the meeting was presenting the ABBV-706 (SEZ6 ADC) for R/R SCLC - with simultaneous publication in @NatureMedicine - these waterfalls plots!! Happy to be able to share the full data. @SclcSMASHERS @LUNGevity @UTMDAnderson

keyboard_arrow_left Previous keyboard_arrow_right Next

Dr. @drshieldsmd gives a great discussion on SCLC at #ASCO26. Tarlatamab update shows the drug raises the bar but points out importance of ICANS awareness. Is it higher in its with brain metastases?

keyboard_arrow_left Previous keyboard_arrow_right Next

As many other oncologists will also attest, we were taught this was a dead end It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted And yet here we are, with truly meaningful survival curves👇 Inspiration on multiple levels #ASCO26

Dr. Catharine Young @DrCatharineY

4 weeks ago

What I love about this news is that this is not simply a new pancreatic cancer drug. It’s that KRAS, one of cancer biology’s most notorious undruggable targets, has finally become druggable. A powerful reminder that persistence in science can eventually unlock the impossible.

21 231 1K 153K 76

DeLLphi-304: Tarlatamab vs Chemo for Brain Mets in Relapsed SCLC ▫️Median CNS PFS 6.5 vs 4.2 mos ▫️Intracranial CR: 14.9% vs 5.4% @g_mountzios #ASCO26

keyboard_arrow_left Previous keyboard_arrow_right Next

#ASCO2026 | LORIN Phase II Neoadjuvant lorlatinib in stage III ALK+ NSCLC delivered impressive results: pCR 47%,MPR 81%,ORR 84%, 75% surgical conversion in initially unresectable disease Small, single-arm study? Absolutely. Randomized confirmation needed? Of course.Practice changing? Debatable. But if I see a stage III ALK+ patient tomorrow, these data would be very hard for me to ignore. I probably wouldn’t hesitate to discuss a neoadjuvant ALK-directed approach at the MDT. #LungCancer #NSCLC #ALK #Lorlatinib #PrecisionOncology #ASCO26

keyboard_arrow_left Previous keyboard_arrow_right Next

🆙 #ASCO26 #LCSM Rapid Oral 🔥Autologous NK Cell Consolidation after 1L Chemoradiotherapy for LS-SCLC ✅mPFS 11.92 vs 6.5m (HR 0.38; p=0.01) ✅mOS 27.13 vs 15.6m (HR 0.41; p=0.02) 🎙️Dr. Jiuwei Cui 🔢8013 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO @IASLC

keyboard_arrow_left Previous keyboard_arrow_right Next

There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines nejm.org/doi/full/10.10…